Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3841136 with or without tirzepatide in Japanese participants with obesity or overweight
NCT06297616Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2024
- Primary completion
- Nov 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of eloralintide in obesity (6 arms), sponsored by Eli Lilly and Company. Primary endpoint: Serious Adverse Events Related to Study Drug Administration at 22 weeks. Started Apr 2024; status: completed.
02
Drugs
eloralintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06297616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06297616.